Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2026 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
April 02, 2026 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
April 01, 2026 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
March 19, 2026 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
March 03, 2026 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
March 02, 2026 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
February 26, 2026 07:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo®...
February 19, 2026 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended...
February 04, 2026 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
February 02, 2026 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...